ADMA Biologics - ADMA Stock Forecast, Price & News

4 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for ADMA Biologics in the last twelve months. There are currently 3 buy ratings and 1 strong buy rating for the stock. The consensus among Wall Street research analysts is that investors should "buy" ADMA shares.
View ADMA analyst ratings or view top-rated stocks.

4 brokerages have issued 12-month price targets for ADMA Biologics' stock. Their ADMA share price forecasts range from $3.00 to $5.00. On average, they expect the company's stock price to reach $4.13 in the next twelve months. This suggests a possible upside of 69.8% from the stock's current price.
View analysts price targets for ADMA or view top-rated stocks among Wall Street analysts.

ADMA Biologics' stock was trading at $1.41 at the start of the year. Since then, ADMA shares have increased by 72.3% and is now trading at $2.43.
View the best growth stocks for 2022 here.

The company is scheduled to release its next quarterly earnings announcement on Wednesday, November 9th 2022.
View our ADMA earnings forecast.

ADMA Biologics, Inc. (NASDAQ:ADMA) released its earnings results on Wednesday, August, 10th. The biotechnology company reported ($0.07) EPS for the quarter, topping the consensus estimate of ($0.09) by $0.02. The biotechnology company earned $33.91 million during the quarter, compared to analysts' expectations of $31.17 million. ADMA Biologics had a negative trailing twelve-month return on equity of 54.78% and a negative net margin of 66.44%. During the same period last year, the company earned ($0.15) EPS.

ADMA Biologics issued an update on its FY 2025 earnings guidance on Friday, September, 9th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $300.00M-.

9 employees have rated ADMA Biologics Chief Executive Officer Adam S. Grossman on Glassdoor.com. Adam S. Grossman has an approval rating of 29% among the company's employees. This puts Adam S. Grossman in the bottom 10% of approval ratings compared to other CEOs of publicly-traded companies.

Based on aggregate information from My MarketBeat watchlists, some companies that other ADMA Biologics investors own include Matinas BioPharma (MTNB), Pennsylvania Real Estate Investment Trust (PEI), OrganiGram (OGI), Gran Tierra Energy (GTE), Tilly's (TLYS), Bionano Genomics (BNGO), Novan (NOVN), CNBX Pharmaceuticals (CNBX), Zosano Pharma (ZSAN) and DHT (DHT).

ADMA Biologics trades on the NASDAQ under the ticker symbol "ADMA."

Shares of ADMA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of ADMA stock can currently be purchased for approximately $2.43.

ADMA Biologics (NASDAQ:ADMA) has a market capitalization of $477.15 million and generates $80.94 million in revenue each year. The biotechnology company earns $-71,650,000.00 in net income (profit) each year or ($0.42) on an earnings per share basis.

The company employs 527 workers across the globe.

ADMA Biologics' mailing address is 465 STATE ROUTE 17, RAMSEY NJ, 07446. The official website for the company is www.admabiologics.com. The biotechnology company can be reached via phone at (201) 478-5552, via email at info@admabio.com, or via fax at 201-478-5553.